Tarlatamab + Durvalumab
Phase 3Active 2 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small-Cell Lung Cancer
Conditions
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Trial Timeline
Jun 5, 2024 → Sep 30, 2028
NCT ID
NCT06211036About Tarlatamab + Durvalumab
Tarlatamab + Durvalumab is a phase 3 stage product being developed by Amgen for Extensive-Stage Small-Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06211036. Target conditions include Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer.
What happened to similar drugs?
0 of 6 similar drugs in Extensive-Stage Small-Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (5)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06211036 | Phase 3 | Active |
Competing Products
20 competing products in Extensive-Stage Small-Cell Lung Cancer